ISSN- 2230-7346
Journal of Global Trends in Pharmaceutical Sciences

SELF- MICROEMULSIFYING DRUG DELIVERY SYSTEMS: AN INNOVATIVE PARADIGM FOR OPTIMIZED DRUG DELIVERY

Surisetty Sridevi*, Sameera Begum, Palla Akshaya Reddy

Department of Pharmaceutics, Malla Reddy College of Pharmacy, Hyderabad, India

*Corresponding author E-mail: sridevikanuri19@gamil.com

ARTICLE

Key words:
SMEDDS, bioavailability, solubility enhancement, poorly water-soluble drugs, microemulsions, surfactants, co-surfactants.

Access this article online
Website:
https://www.jgtps.com/
Quick Response Code:

ABSTRACT

Self-Microemulsifying Drug Delivery Systems (SMEDDS) are emerging as a promising approach to enhance the solubility, stability, and bioavailability of poorly water-soluble drugs, which are a major challenge in the development of oral pharmaceutical formulations. SMEDDS are isotropic mixtures composed of oils, surfactants, co-surfactants, and active pharmaceutical ingredients (APIs). Upon contact with aqueous environments, typically in the gastrointestinal tract, SMEDDS spontaneously form microemulsions or nano emulsions, which are thermodynamically stable and capable of improving the solubility of lipophilic drugs. This self-emulsification process is highly advantageous for drugs with low water solubility, as it aids in the formation of fine emulsions that facilitate the drug's absorption through the Intestinal mucosa. The key advantages of SMEDDS include enhanced drug dissolution rate, improved bioavailability, and the ability to circumvent the limitations associated with traditional drug formulations. In addition to solubility enhancement, SMEDDS can also reduce variability in drug absorption due to food effects and improve therapeutic outcomes. The selection of appropriate excipients, including oils, surfactants, and cosurfactants, is crucial to the success of SMEDDS formulations, as it affects both the stability of the microemulsion and the solubilization efficiency of the drug. Characterization of SMEDDS involves techniques such as droplet size analysis, zeta potential measurement, transmission electron microscopy (TEM), and stability studies to ensure the formulations' quality and performance. However, challenges remain, such as the potential toxicity of surfactants, scalability for commercial production, and the need for optimization to balance the formulation components effectively. This review aims to provide an overview of the formulation principles, advantages, characterization methods, and current challenges in the development and application of SMEDDS. It highlights their significance in the pharmaceutical industry for improving the bioavailability of poorly soluble drugs

INTRODUCTION

Self- Micro emulsifying Drug Delivery Systems (SMEDDS) are a class of advanced drug delivery systems that have gained significant attention for their ability to improve the solubility, stability, and bioavailability of poorly water-soluble drugs. The challenge of formulating drugs with low aqueous solubility remains one of the major obstacles in pharmaceutical development, especially with the increasing number of

lipophilic drugs in the pipeline. SMEDDS are designed to address this issue by facilitating the dissolution of hydrophobic drugs in the gastrointestinal (GI) tract. These systems are typically composed of an oil phase, surfactants, co-surfactants, and the active pharmaceutical ingredient (API). Upon contact with water or gastrointestinal fluids, SMEDDS spontaneously self-emulsify, forming microemulsions or nanoemulsions that enhance the drug's solubility and promote its absorption (27). The principle behind SMEDDS is their ability to reduce the interfacial tension between the oil phase and water, allowing for the formation of stable emulsions. Surfactants and co-surfactants are key excipients in this process. Surfactants, which are amphiphilic molecules, act to lower the interfacial tension between the oil and water phases, stabilizing the resulting microemulsion. Co-surfactants, typically smaller molecules such as alcohols, further assist in enhancing the emulsification process and improving the stability of the final formulation. When a SMEDDS formulation is introduced to the aqueous phase (e.g., stomach fluids), the system self-assembles into a fine emulsion that enhances the dissolution rate of lipophilic drugs, allowing them to be more readily absorbed in the gastrointestinal tract (33). The development of SMEDDS requires a careful selection of components, including the oil, surfactant, and co-surfactant, to ensure the system forms a stable microemulsion under gastrointestinal conditions. The oil phase often consists of medium-chain or long-chain triglycerides, which are known for their ability to solubilize lipophilic drugs. Surfactants are typically non-ionic or anionic, chosen based on their emulsifying properties and biocompatibility. The co-surfactant plays a crucial role in reducing the interfacial tension and increasing the solubilization capacity of the system . The proportion of these components must be optimized to create an isotropic mixture that can self-emulsify efficiently, thus achieving the desired therapeutic effect. SMEDDS formulations can be developed as soft or hard gelatin capsules, or they can be presented as liquids for further formulation into dosage forms. The self-emulsifying nature of these systems ensures that they are stable in the GI tract, allowing the active ingredient to remain solubilized and, therefore, more readily available for absorption. In this way, SMEDDS provide a practical solution for the formulation of poorly soluble drugs, particularly those with high lipophilicity that are otherwise poorly absorbed when taken orally. The efficiency of SMEDDS in improving drug dissolution and bioavailability makes them an attractive option for enhancing the therapeutic efficacy of many drugs that are otherwise difficult to deliver (4). Despite their promising potential, the formulation and manufacturing of SMEDDS come with challenges. The excipient selection must account for factors like biocompatibility, toxicity, and stability under various storage conditions. Additionally, there is the need for large-scale manufacturing processes that maintain the quality and stability of the formulations, which can be technically challenging. Furthermore, the safety and toxicity profiles of surfactants and co-surfactants need to be carefully evaluated, particularly when these systems are intended for use in human patients (5). As such, while SMEDDS represent a significant advancement in oral drug delivery technology, their development and commercialization require overcoming several technical and regulatory hurdles. The various fashion is employed to enhance oral bioavailability of the deficiently water-answerable drug, the oral route has been the ideal route of drug administration for the endless treatment of conditions as it offers more patient compliance (1). 40 of new drug applicants show low solvency in water, which is a test being developed of the ideal oral

solid capsule form as far as expression development and bioavailability of new pharmaceutical drug (1, 2). various strategies are used for perfecting the bioavailability of those specifics like the tar arrangement, pH change, β cyclodextrin complex, microemulsion, and so forth (3). SMEDDS is the swish and utmost preferable system for the enhancement of oral bioavailability. SMEDDS are class of emulsion that has gotten specific consideration as a system for elevation oral bioavailability of poor answerable drugs (4). SMEDDS or tone-emulsifying oil painting oil phrasings (SEOF) are characterized as isotropic mixes of natural and synthetic oils, cancel these words, surfactants, or also again, at least one hydrophilic cleanser and co-solvents surfactants (2, 3). SEDDS naturally produce mixes with a drop size nearly in the range of 100 and 300 nm while SMEDDS can have drop size nearly near 50 nm (3,5).



Fig 1. Self-Micro Emulsifying Drug Delivery System (SMEDDS)

ADVANTAGES

Advantages of Self Micro-Emulsifying Drug Delivery Systems (SMEDDS):

Self-Micro-Emulsifying Drug Delivery Systems (SMEDDS) have surfaced as a promising approach to enhance the bioavailability of inadequately water-answerable medicines. These systems offer several advantages over traditional medicine delivery styles.

Enhanced Solubility and Bioavailability

Bettered medicine dissolution SMEDDS form fine oil painting- in- water microemulsions upon contact with waterless fluids in the gastrointestinal (GI) tract, significantly adding the medicine's face area and dissolution rate.

Improved Drug Delivery: Protection from enzymatic declination the microemulsion terrain can cover medicines from enzymatic declination in the GI tract, enhancing medicine stability. Targeted medicine delivery SMEDDS can be formulated to target specific regions of the GI tract, perfecting medicine efficacy and reducing side goods.

Formulation and Manufacturing Advantages: Ease of make SMEDDS are reasonably straightforward to define and gage - up compared to other lipid- grounded pharmaceutical conveyance frameworks.

Case Compliance and Safety: Advanced case compliance SMEDDS frequently affect in reduced dosing frequency and bettered medicine tolerability, enhancing patient adherence to remedy.

Reduced gastrointestinal vexation SMEDDS can minimize gastrointestinal side goods associated with inadequately water-answerable medicines. The SMEDDS formula can palliate the infection that goods from extended contact between the medicine and the stomach wall because the micro-sized driblets support the medicine’s great distribution along the GIT and are fast moved by means of GIT. SMEDDS can efficaciously shape poor water-soluble capsules with a confined immersion figure and dissolution figure, performing in a stable tube profile. The constant tube stages of the ineffectively fluid detergent cure display the introductory phase of medicines assimilation. Decomposition. SMEDDS outperform mixes in expressions of stability due to their low energy input and simple manufacturing manner. SMEDDS can be made with easy mixing tools, and the training time is shorter than that of mixes.

DISADVANTAGES: Expression and Process-Affiliated Challenges: Complex Formulation SMEDDS bear careful

optimization of oil painting, surfactant-surfactant, and medicine factors. Achieving the asked balance can be complex and time-consuming. Physical Stability SMEDDS can be susceptible to phase separation, drop growth, and other physical precariousness during storehouse and running.

Biopharmaceutical Challenges: Limited Lymphatic immersion While SMEDDS can enhance oral immersion; their eventuality for lymphatic transport is limited, which might be a disadvantage for certain medicines. In Vitro- In Vivo Correlation Predicting in vivo performance grounded on in vitro data can be challenging due to the complex physiological terrain of the gastrointestinal tract.

Clinical and Regulatory Challenges: Regulatory Hurdles Developing SMEDDS-grounded products frequently requires expansive preclinical and clinical studies to meet nonsupervisory conditions. Intellectual Property guarding the intellectual property of SMEDDS phrasings can be challenging due to the eventuality for expression variations.

Other Considerations: Environmental Impact the use ocertain canvases and surfactants in SMEDDS phrasings may raise enterprises about their environmental impact.

Limited connection SMEDDS are primarily suitable for inadequately water-answerable medicines with high permeability. Their effectiveness for other medicine classes may be limited. Based on Type of Micro emulsion: Water-in-Oil (W/O) SMEDDS: In this system, water droplets are dispersed in an oily phase. These are useful for drugs that require slow release and can benefit from a longer residence time in the body. Oil-in-Water (O/W) SMEDDS: Here, oil droplets are dispersed in water, which is the more commonly used system. O/W SMEDDS are generally employed to improve the solubility and absorption of lipophilic drugs by enhancing their interaction with the gastrointestinal tract.(27)

2. Based on Composition: Conventional SMEDDS: These typically contain oils (e.g., medium-chain triglycerides), surfactants (e.g., polysorbates), and co-surfactants (e.g., ethanol). These formulations work by forming microemulsions upon dispersion in the gastrointestinal fluids. Nano-SMEDDS: These are a subset of SMEDDS, designed to form smaller droplets (typically in the nanometer range), which enhances the rate of drug absorption by increasing surface area. Solid SMEDDS: These are designed to overcome issues like the instability of liquid SMEDDS during storage, particularly in environments with high humidity. In solid SMEDDS, the liquid components of the formulation are adsorbed onto an inert carrier, creating a solid formulation that can still form microemulsions upon contact with aqueous media.

Based on Drug Characteristics: Lipophilic Drug-Based SMEDDS: These are primarily used for poorly water-soluble, lipophilic drugs that have low bioavailability due to poor solubility in the gastrointestinal tract. Amphiphilic Drug-Based SMEDDS: These involve drugs that have both hydrophilic and lipophilic properties, necessitating a specialized approach to formulation.(5)

4. Based on Droplet Size: Sub-micron SMEDDS: These formulations typically produce microemulsions with droplet sizes between 100 nm and 1 μm. They are beneficial for improving drug absorption through enhanced drug diffusion and increased surface area.

Micro-SMEDDS: The droplet size ranges between 1 to 10 μm, and these systems are typically more stable, making them suitable for longer storage times and consistent performance.

5.Based on the Mode of Administration

Oral SMEDDS: These are the most common types of SMEDDS, where the formulation is ingested orally to improve the bioavailability of drugs with poor solubility. Parenteral

SMEDDS: Though less common, SMEDDS can also be used for parenteral (injectable) delivery, where the formulation improves the solubility and stability of drugs intended for injection. SMEDDS 6Y(Type III B structures) are defined as isotropic dyads of natural or synthetic oils, stable or liquid surfactants, or one or further hydrophilic cleansers and co- cleansers/ surfactants that have capability to shape satisfactory oil painting oil- in- water(o/ w) microemulsion upon slight agitation followed by means of dilution in arid media, which include GI fluids (20) .These systems are developed through the use of a lipid provider which improves the gastro intestinal absorption of deficiently water answerable capsules, permits the drug to stay in dissolved area by shielding the drug from enzymatic response, thermodynamically stable, without difficulty manufactured and applicable for oral drug transport (16). Nonionic surfactants are generally asked in factors as they've lower (13-19) .CMC cost, they 're much less poisonous, offers a lower emulsion stability over a wide variety of pH and ionic strength. attention of co- surfactant plays a top position in lipid predicated fully expression. Selection of surfactant and co- surfactant is necessary for the solubilization of drug. Organic cleansers analogous as ethanol, propylene glycol, polyethylene glycol are applicable for oral drug transport (16). As oral direction has continually been favored and has ruled over different routes of administration due to its- invasiveness, and cost effectiveness thus it turns out to be essential that drug must have some arid in addition to a numerous lipid solubility for advanced absorption thru this path. The oral course isn't always suitable for those chemical realities which showcase terrible arid solubility (19). If a class II drug can be maintained in a solubilize state in the lumen of the gut bone can achieve an absorption problem more like that of a class I drug.



Figure 1: A Typical Representation of Biopharmaceutical Classification System [13]

Expression strategies can do little to meliorate the absorption of class IV and III drugs which are limited by poor membrane Permeability (15)

MECHANISM OF SELF EMULSIFICATION: [21-23]: The emulsion's free power can be defined as the subsequent formulation:

$\Delta G = \sum N\pi r2$ In which "G" denotes the droplet's free strength, "r" denotes its radius, and "N" denotes the interfacial electricity. This circumstance shows that the decrease the interfacial energy, the decrease the free electricity. when the energy required for droplet Formation exceeds the energy require for dispersion, self-emulsification takes place. Elements impacting of SMEDDS Composition of Oil Phase: The choice of oil phase is critical in the formulation of SMEDDS. Oils like medium-chain triglycerides (MCT), long-chain triglycerides (LCT), or phospholipids are typically used. The oil phase solubilizes lipophilic drugs and influences the self-emulsification process.



Surfactant and Co-Surfactant Selection

Surfactants play a crucial role in the formation of microemulsions by reducing the interfacial tension between the oil and aqueous phases. Nonionic surfactants such as Tween 80, Cremophor EL, and polyoxyethylene-based surfactants are commonly used. Co-surfactants, such as ethanol or propylene glycol, aid in reducing the required surfactant concentration and enhancing the microemulsions stability.(42)

Hydrophilic-Lipophilic Balance (HLB)

The HLB of the surfactant mixture significantly affects the self-emulsification properties of SMEDDS. A suitable HLB range (typically between 10 and 16) ensures that the surfactant and co-surfactant system can form stable microemulsions, promoting drug solubilization and improving **bioavailability. Drug-to-Excipient Ratio:** The ratio of drug to excipients directly influences the performance of SMEDDS. A high drug-to-excipient ratio can lead to reduced solubilizing capacity, resulting in incomplete drug dissolution, while a low ratio can cause an excess of excipients, which may affect the overall stability and viscosity of the formulation. An optimal balance is essential for the efficiency of SMEDDS.19)

Particle Size and Distribution: The size of the droplets in the microemulsion formed by SMEDDS should be in the range of 10-100 nm to ensure optimal drug absorption. Smaller particle sizes increase the surface area available for absorption, leading to faster drug dissolution and enhanced bioavailability. The uniformity of particle size distribution is also vital for the reproducibility and stability of the formulation.

pH and Ionic Strength of the Medium: The pH and ionic strength of the gastrointestinal tract can affect the behavior of the SMEDDS. For instance, acidic environments (stomach) may alter the stability of the microemulsion, while higher pH (intestinal tract) could enhance the self-emulsification process. Buffering agents may be used to stabilize the formulation under varying pH conditions

Emulsification Time and Temperature, The time required for emulsification and the temperature at which emulsification occurs are important factors. Higher temperatures can accelerate the emulsification process, but they may also affect the stability of the formulation or the drug. The formulation should be designed to self-emulsify rapidly under physiological conditions, typically at body temperature (37°C).

Viscosity: The viscosity of SMEDDS affects its ease of administration and the rate at which the microemulsion forms in the gastrointestinal tract. High viscosity can slow down the emulsification process, whereas low viscosity formulations may not provide adequate solubilization. Achieving an optimal viscosity is important for both the drug's release and the formulation's ease of use.

Stability and Storage Conditions

The physical and chemical stability of SMEDDS is crucial for ensuring the effective delivery of the drug. Factors such as temperature, humidity, and light exposure can affect the integrity of the formulation.

SMEDDS are sensitive to changes in environmental conditions.

Precipitation and Supersaturation

One of the challenges in SMEDDS formulation is the potential for drug precipitation upon dilution in the gastrointestinal tract. To overcome this, SMEDDS formulations may incorporate solubilizing agents or surfactants to maintain the drug in a supersaturated state and prevent precipitation.

Remedy and nature of medicinal (21,22)

Capsules brought at greatly unreasonable boluses aren't applicable for SMEDDS but they appear astonishing solvency in at negligible one of the variables, particularly the lipophilic part. SMEDD has the most extreme issue regulating capsules with moo

water and lipid dissolvability (by and large with log P values of generally)

Resistance of the lipophilic member (23,24)

The release of medicine from microemulsions is directed through parameters relative as restriction of the lipid lattice (23). The HLB, the length of chain and fat sharp degree of unsaturation, and the atomic weight of micronized all affect the resistance of the drop for their capability to levee crystallization and, hence, set up and spare the supersaturated state for an amplified time (24)

4. Formulation optimization of SMEDDS (25, 26)

1. Preformulation Studies: Solubility Study: Assess the solubility of the drug in oils, surfactants, and co-surfactants. Compatibility Study: Evaluate interactions between drug and excipients.

2. Phase Diagram Construction: Ternary Phase Diagram: Determine the optimal ratio of oil, surfactant, and co-surfactant to form a stable microemulsion.

3. Preparation of SMEDDS

Oil Phase Mixing: Dissolve the drug in selected oils. Surfactant and Co-Surfactant Mixing: Blend surfactants and co-surfactants. Homogenization: Mix all components thoroughly to achieve uniformity.

4. Optimization

Droplet Size Optimization: Adjust surfactant and co-surfactant ratio for desired droplet size. Viscosity and Self-Emulsification Efficiency: Fine-tune the formulation for quick emulsification and appropriate viscosity.

5. Characterization: Self-Emulsification Test: Evaluate how quickly the SMEDDS forms a stable microemulsion when added to water. Droplet Size Distribution: Measure the size of the droplets using techniques like DLS (Dynamic Light Scattering).

Stability Testing: Perform long-term and accelerated stability tests.

6. *In Vitro* Drug Release Testing:

Dissolution Testing: Measure the drug release profile under simulated conditions.

7. **Dosage Form Selection**: Capsules, Liquids, or Solids: Based on formulation characteristics, choose an appropriate dosage form for the SMEDDS (e.g., soft gel capsules, oral liquids, or solid SMEDDS).
8. **Stability and Storage Studies:** Long-Term Storage: Test for stability under various temperature and humidity conditions.

4.1 Components of SMEDDS (27-34)

1. Phases: Typically consists of lipophilic (fat-soluble) substances, which act as the solvent for poorly soluble drugs**.**

Common oils include medium-chain triglycerides (MCT), long-chain triglycerides (LCT), and vegetable oils.

2. Surfactants: These are surface-active agents that reduce the interfacial tension between oil and water phases, facilitating the formation of microemulsions. Surfactants can be either ionic (anionic or cationic) or non-ionic. Non-ionic surfactants, like Tween and Span, are most commonly used in SMEDDS because of their mildness and stability.

3. Co-Surfactants

Co-surfactants are often added to the formulation to help stabilize the system, particularly in adjusting the phase behavior and improving the emulsification properties. Examples include ethanol, propylene glycol, and polyethylene glycol (PEG).

4. Active Pharmaceutical Ingredient (API)

The drug itself, which is typically hydrophobic, is solubilized in the oil phase. The SMEDDS formulation allows the drug to be released in a more soluble form, enhancing its bioavailability.

6. Water Phase (optional): While the formulation itself is anhydrous (no water), it interacts with water in the gastrointestinal tract. When the SMEDDS comes into contact with water (e.g., stomach fluid), it forms a microemulsion.

7. Other Excipients (optional) Antioxidants to prevent degradation of sensitive drugs. Preservatives to prevent microbial growth**, especially in liquid formulations.**

Flavoring agents in oral formulations for better patient compliance.

SOLUBILITY OF ACTIVE DRUG SMEDDS

Self-Microemulsification Process: SMEDDS formulations are composed of lipids, surfactants, and co-surfactants, which, when in contact with water, spontaneously form microemulsions. This process significantly enhances the solubility of poorly water-soluble drugs by dispersing them into fine droplets.(35)

Lipid Contribution to Solubility: Lipids are a crucial component in SMEDDS, enhancing the solubilization of lipophilic drugs. The type of lipid, such as medium-chain triglycerides, affects the solubility capacity of the formulation. Lipid solubilizing power directly influences the bioavailability of the drug. (36)

Surfactants: Surfactants lower the interfacial tension between the oil and water phases, promoting the formation of microemulsions and improving the solubility of hydrophobic drugs. The choice and concentration of surfactants are key to achieving optimal solubility. (37)

Co-Surfactant: Co-surfactants (e.g., alcohols) reduce the interfacial tension even further, stabilizing the microemulsion and improving drug solubility. This combination ensures that both hydrophilic and lipophilic drugs are effectively solubilized. (38)

Improved Solubilitly Water-Soluble Drugs: SMEDDS are designed specifically to enhance the solubility of poorly water-soluble, lipophilic drugs by converting them into a solubilized form within the microemulsion. This enhances the drug's dissolution rate, which is crucial for improving bioavailability.(39)

Particle Size and Solubility: solubility of drugs in SMEDDS is enhanced by the reduced droplet size of the microemulsion. Smaller droplet sizes lead to a higher surface area, facilitating faster dissolution and improved solubility of the drug. (40)

Temperature Sensitivity: Temper a role in the solubilization process. Higher temperatures can increase the solubility of certain drugs in SMEDDS by altering the viscosity and phase behavior of the formulation. However, excessive heat can destabilize the system. (41)

Effect of pH on Solubility: pH can influence solubility of drugs in SMEDDS, especially for weakly acidic or basic drugs. The pH of the gastrointestinal tract or the formulation's pH can alter drug ionization, affecting its solubility and absorption. (42).

***In Vivo* Solubility and Bioavailability**: The solubilment in SMEDDS does not always correlate directly with in vivo bioavailability. In vivo absorption depends on the ability of the microemulsion to release the drug effectively in the digestive tract. (43)

Stability and Long-Term Solubility: The stability of SMEDDS s is critical for maintaining solubility over time. The formulation's resistance to phase separation and its ability to remain homogeneous ensure consistent solubility and drug release throughout the shelf life of the product. (44)

Characterizations of SMEDDS

Droplet size:

Bitsy ways, Photon correlation spectroscopy or a Coulter Nanosized are generally used to determine the drop size of conflation. Droplet size is an important factor in tone-emulsification performance because it determines the rate and extent of medicine

release, as well as the stability of the microemulsion (52).

Electron bitsy studies (53) Face characteristics of micro- emulsion are studied using snap- fracture electron microscopy.

Procedure: Prepare a sample of the SMEDDS and apply it onto a suitable grid or surface.

Use **SEM** for surface morphology or **TEM** for internal structure observation.

Dry the sample, often coating it with gold for SEM or using a grid for TEM. Analyze the droplet size, shape, and overall microstructure under the electron microscope. Zeta implicit dimension, It's used to identify the charge of the driblets.

Procedure: Prepare the SMEDDS formulation and dilute it in an appropriate medium. Measure the zeta potential using a zetasizer, applying an electric field to the sample. The instrument calculates the electrophoretic mobility, from which the zeta potential is derived. Analyze the stability based on the zeta potential value: >30 mV indicates high stability.

Determination of emulsification time:

This process is used for estimation of the time taken for emulsification. In this effectiveness of emulsification of colorful compositions of the surfactants and lipids is quantified using a rotating paddle to promote emulsification in a crude nephelometer (54).

Flyspeck particle size distribution

Dynamic light scattering ways is used for dimension of flyspeck size distribution of the microemulsion. This utilizes the change in scattered light intensity to measure the haste of the Brownian prolixity and accordingly the dispersed driblets. flyspeck size distributions can be further vindicated by cryogenic transmission electron microscopy(cryo-TEM). Cryo- TEM offers the advantage of imaging the flyspeck sizes and shapes (55).

Conductivity measures: Conductivity measures are suitable to determine the point of thirsty phase addition where the system changes from having oil painting oil nonstop to a water nonstop phase. It also helps in monitoring of percolation or phase inversion sensations (56).

LIMITATIONS: While Self-Microemulsifying Drug Delivery Systems (SMEDDS) offer several advantages, they also have some limitations:

1. Poor Stability in Harsh Conditions: SMEDDS can be unstable in extreme conditions, such as high temperatures or acidic environments (e.g., in the stomach), leading to phase separation.

2. Size Dependency: SMEDDS often have droplet sizes in the nanometer or micrometer range, which can lead to variations in drug release and bioavailability depending on the system's preparation.

3. **Drug Solubility Issues:** The effectiveness of SMEDDS is highly dependent on the solubility of the drug in the oils and surfactants used, and some drugs may not integrate well into the formulation.

Complex Manufacturing Process: The preparation of SMEDDS requires precise formulation of oils, surfactants, and co-solvents, making the manufacturing process more complex and expensive.

APPLICATIONS

Improved bioavailability: SMEDDS enhance the absorption of poorly water-soluble drugs, improving their bioavailability.

Oral drug delivery: They facilitate the oral delivery of lipophilic drugs by improving solubility and absorption in the gastrointestinal tract.

Improved stability: SMEDDS offer better chemical and physical stability for drugs sensitive to degradation.

Transdermal drug delivery: They are used for enhancing the permeation of drugs through the skin for topical and transdermal applications **Controlled and Sustained**

Release: SMEDDS allow for the controlled release of drugs, extending their therapeutic effect over time **Targeted Drug Delivery:**
They enable targeted delivery of drugs to specific sites, such as tumors, to reduce side effects.
Solubilization of Hydrophobic Drugs: SMEDDS solubilize hydrophobic drugs, improving their bioavailability and efficacy.
Improved Patient Compliance: By reducing the dosage frequency and side effects, SMEDDS enhance patient adherence to treatment regimens.
Nutraceuticals and Cosmetics: They are also used in the formulation of nutraceuticals and cosmetics for improved efficacy of active ingredients.

CONCLUSION

In conclusion, Self-Microemulsifying Drug Delivery Systems (SMEDDS) represent a promising approach for enhancing the bioavailability and stability of poorly soluble drugs, offering improved solubilization, controlled release, and targeted delivery. As the pharmaceutical industry continues to face challenges with formulating drugs with low water solubility, SMEDDS are poised to play a key role in improving the therapeutic efficacy of a wide range of drugs. With ongoing advancements in formulation technology and a growing understanding of drug absorption mechanisms, SMEDDS have the potential to significantly impact the future of drug development, leading to more effective and patient-friendly therapies in the market.

REFERENCES

1. Maurya, Arya, (2017). Self-micro emulsifying drug delivery systems (smedds): a review on physico-chemical and biopharmaceutical aspects. Journal of Drug Delivery and Therapeutics, 7 (3), 55–65.
2. Ramya, (2019). Design and Evaluation of a Self-Emulsifying Drug Delivery System of Aripiprazole. Indian Journal of Pharmaceutical Sciences, 81 (6), 1089–1098.
3. Gumaste, (2017). Development of solid SEDDS, VI: Effect of precoating of Neu Silin® US2 with PVP on drug release from adsorbed self-emulsifying lipid-based formulations. European Journal of Pharmaceutical Sciences, 110, 124–133.
4. Ramesh, (2019). Design and Evaluation of Telmisartan SMEDDS for Enhancing Solubility and Dissolution Rate. International Journal of Pharmaceutical Sciences and Nanotechnology, 12 (6), 47214730.
5. Patel, M. (2010). A self-micro emulsifying drug delivery system (SMEDDS). International Journal of Pharmaceutical Sciences Review and Research, 4 (3), 29–35.
6. Ravikant: Compressive Review on Self-Emulsifying Drug Delivery System for Diabetes Mellitus. International Journal of Research and Analysis in Science and Engineering 2022; 2: 36–44.
7. Vadlamudi: In-vitro and pharmacodnamic characterization of solidified self-micro emulsified system of quetiapinefumarate. Journal of Pharmaceutical Investigation 2018; 49: 161–172.
8. Pobirka: Solidification of SMEDDS by fluid bed granulation and manufacturing of fast drug release tablets. International Journal of Pharmaceutics 2020; 583:119377
9. Jankovic, Evaluation of critical parameters in design and differentiation of selfemulsifying drug delivery systems for oral delivery of acyclovir. Inter J of Pharmaceutics 2016; 497: 301-11.
10. Sanjib Bahadur, Review of Formulation and Evaluation of Self-

Micro Emulsifying Drug Delivery System (Smedds).Scientific Journal Science Rise: Pharmaceutical Science 2020;26-35.
11. Gahlawat N, Review on: Recent Development in Self-Micro-Emulsifying Drug Delivery System: An Overview. Asian Journal of Pharmaceutics, 2019;13(1):59- 60.
12. Akula, Review on: Self-Micro Emulsifying Drug Delivery System:
13. Attractive Strategy for Enhance Therapeutic Profile. International Scholarly Research Notices, 2014; 11(8): 1-4.
14. Potphode. Review on; Self-Micro Emulsifying Drug Delivery System:
15. Approach for Enhancement Bio viability of Poorly Water-Soluble Drugs. Asian J. Pharma Tech, 2016; 6(3): 63-65.
16. P. Reddy, Review on: Self-Micro Emulsifying
17. Drug Delivery System. International Journal of Research in Pharmaceutical and Nano Sciences, 2013; 2(3):319.
18. Pawar, Review on: Self-Micro Emulsifying Drug Delivery System (SMEDDS): A Promising Drug Delivery System for Enhancement of Bioavailability. Indian Journal of Drug, 2016; 4(3):6-7.
19. P. Tripura, Formulation and Evaluation of SMEDDS Containing Febuxostat by Employing Arachis Oil and Labrasol as Oil and Surfactant System. World Journal of Pharmaceutical Research, 2018; 7(11): 543- 545. 19.
20. Reddy S, Review on Self- Micro-Emulsifying Drug Delivery System. International Journal of Research in Pharmaceutical Sciences, (2011); 2(3):383- 386.
21. Sharma. Review on: Self-Micro-Emulsifying Drug Delivery System: A Strategy to Improve Oral Bioavailability. Ars Pharmaceutical, 2016; 57(3):102, 99.
22. Sharma, Review on: SMEDDS: A Novel Approach for Lipophilic Drugs. International Journal Pharmaceutical Sciences and Research, 2012; 3(8):2441-2444
23. Patte war SV, Review on: Self-Micro Emulsifying Drug Delivery System: A Lipid Based Drug Delivery System. International Journal of Pharmaceutical Sciences and Research, 2016; 7(2): 443-448.
24. Sharma V, (2012). SMEDDS: a novel approach for lipophilic drugs. Int J Pharm Sci Res 3:2441.22.Akula S, Gurram AK, Devireddy SR. (2014). Self- micro emulsifying drug delivery systems: an attractive strategy for enhanced therapeutic profile. Int Sch Res Notices 2014:1811.
25. Rani(2021). Insights into novel excipients of self-emulsifying drug delivery systems and their significance: an updated review. Crit Rev Ther Drug Carrier Syst 38:27–74.
26. Nigade, (2012). Self-emulsifying drug delivery system (SEDDS): a review. Int J Pharm Biol Sci 2:42–52.
27. Rahman, (2013). Role of excipients in successful development of self-emulsifying/micro emulsifying drug delivery system (SEDDS/SMEDDS). Drug Dev Ind Pharm 39:1–19.
28. Betageri GV. (2019). Self-emulsifying drug delivery systems and their marketed products: a review. Asian J Pharm 13:73–84.
29. Pouton CW. (2000). Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-micro

emulsifying' drug delivery systems. Eur J Pharm Sci 11: S93–S8.
30. Kimura M, (1994). Relationship between the molecular structures and emulsification properties of edible oils. Biosci Biotechnology BioChem 58:1258–61.
31. Halder S, (2021). Self-emulsifying drug delivery system of black seed oil with improved hypotriglyceridemic effect and enhanced hepatoprotective function. J Funct Foods 78:104391.30.
32. Gershanik, (1996). Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone. Pharm Dev Technol 1:147–57.
33. Matsaridou, (2012). The influence of surfactant HLB and oil/surfactant ratio on the formation and properties of self-emulsifying pellets and microemulsion reconstitution. AAPS Pharm SciTech 13:1319–30.
34. Gurram A, (2015). Role of components in the formation of selfmicroemulsifying drug delivery systems. Indian J Pharm Sci 77:249–57.
35. Kohli K, Chopra S, Dhar D, et al. (2010). Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discovery, today 15:958–65.
36. Rani S, Rana R, Saraogi GK, et al. (2019). Self- emulsifying oral lipid drug delivery systems: advances and challenges. AAPS Pharm SciTech 20: 1–12. References:
37. Pouton,, & Porter, (2008). "Formulation of self emulsifying drug delivery systems." Advanced Drug Delivery Reviews, 60(6), 611-624.
38. Kunjachan, S., et al. (2014). "Self-emulsifying drug delivery systems (SMEDDS) for improved oral drug delivery." International Journal of Pharmaceutics, 472(1-2), 96-105.
39. Hwang, J., et al. (2013). "Co-surfactants in SMEDDS: Role in improving solubility and bioavailability." Drug Development and Industrial Pharmacy, 39(7), 1061-1071.
40. Shariati, S., et al. (2018). "Impact of surfactant concentration on solubility and dissolution of SMEDDS." Journal of Pharmaceutical Sciences, 107(9), 2301-2309.
41. Emami, J., et al. (2009). "SMEDDS: A promising approach to improve solubility and bioavailability of hydrophobic drugs." International Journal of Pharmaceutics, 374(1-2), 69-78.
42. Javadzadeh, et al. (2009). "The role of SMEDDS in enhancing solubility and bioavailability of poorly soluble drugs." Journal of Controlled Release, 134(3), 103-107.
43. Lu, H., (2006). "Effect of temperature on the solubility of drugs in self-emulsifying systems." International Journal of Pharmaceutics, 310(1), 51-58.
44. Patel,et al. (2006). "Effect of pH and ionic strength on the solubilization of poorly soluble drugs in selfemulsifying systems." Journal of Pharmaceutical Sciences, 95(5), 1004-1013.
45. Ruan, et al.(2014). "In vivo performance of self-emulsifying drug delivery systems." Journal of Pharmaceutical Sciences, 103(11), 3430-3441.
46. Mura, P., et al. (2013). "Stability of self-emulsifying drug delivery systems and their potential for improved solubility." Journal of Drug Delivery Science and Technology, 23(5), 455-465.